Jasper Therapeutics, Inc. (JSPR), a clinical-stage biotechnology company, announced on Friday the pricing of an underwritten public offering to raise $29.6 million in gross proceeds.
The firm has priced an underwritten public offering of about 11.67 million common shares with accompanying common warrants at $2.43 per share and warrant.
The company also offers pre-funded warrants to purchase up to 675,000 common shares and accompanying common warrants, at $2.43 less the $0.0001 exercise price per pre-funded warrant.
The offering is expected to close on or about September 22, subject to closing conditions.
The pre-funded warrants will be immediately exercisable, while common warrants will be exercisable starting six months from issuance at $2.92 per share and will remain exercisable for four years.
The company plans to use the net proceeds to advance preclinical and clinical development of briquilimab in mast-cell driven diseases and for general corporate purposes, including capital expenditures, working capital, and administrative expenses.
On Thursday, Jasper Therapeutic closed trading, 4.25% lesser at $2.4800 on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.